Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Monte Rosa Therapeutics's EV/EBITDA was 103.0× on Jan 30, 2026.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 103.0× | +35.1 |
| 2025 | Dec 31, 2025 | 67.9× | – |
See a number that looks wrong?